Dr. Han on the Importance of pCR in Breast Cancer

Heather ​S. Han, MD, medical oncologist and research director of Breast Oncology, Moffitt Cancer Center, discusses the importance of pathologic complete response (pCR) in breast cancer.

Patients with breast cancer who achieve a pCR following neoadjuvant therapy often have a better outcome compared with patients who do not, Han says. Moreover, pCR has been established as an important prognostic marker in breast cancer. 

Today, pCR continues to be used as a surrogate marker for patients with breast cancer ​following neoadjuvant therapy, explains Han.

Based on available data, the field can better determine the most optimal adjuvant treatment option for patients, Han concludes.